Table 2 Observed values for screening process indicators after HPV testing in the English pilot (first screening round in 2013–2016), and values after standardisation by IMD quintile
Process indicator | 24–29 years | 30–49 years | 50–64 years | ||||||
|---|---|---|---|---|---|---|---|---|---|
N with outcome | Observed % (95% CI) | Standardised % | N with outcome | Observed % (95% CI) | Standardised % | N with outcome | Observed % (95% CI) | Standardised % | |
N screened | 76,277 | 224,400 | 103,206 | ||||||
HPV positive | 20,544 | 26.9% (26.6 to 27.2) | 26.5% | 22,563 | 10.1% (9.9 to 10.2) | 9.9% | 5486 | 5.3% (5.2 to 5.5) | 5.7% |
Referred at baseline | 7898 | 10.4% (10.1 to 10.6) | 10.8% | 7049 | 3.1% (3.1 to 3.2) | 3.2% | 1215 | 1.2% (1.1 to 1.2) | 1.2% |
Referred at any point | 12,692 | 16.6% (16.4 to 16.9) | 16.4% | 12,292 | 5.5% (5.4 to 5.6) | 5.4% | 2860 | 2.8% (2.7 to 2.9) | 2.7% |
CIN2 + a | 4883 | 6.3% (6.2 to 6.5) | 6.1% | 3810 | 1.7% (1.6 to 1.8) | 1.5% | 494 | 0.5% (0.4 to 0.5) | 0.4% |
CIN3 + a | 2903 | 3.8% (3.7 to 3.9) | 3.6% | 2344 | 1.0% (1.0 to 1.1) | 0.9% | 276 | 0.3% (0.2 to 0.3) | 0.3% |